Copyright © Inderes 2011 - present. All rights reserved.
  • Latest
  • Markets
    • Morning Review
    • Stock Comparison
    • Financial Calendar
    • Dividends Calendar
    • Research
    • Articles
    • Insider Transactions
    • Transcripts
  • inderesTV
  • Portfolio
  • Forum
  • Premium
  • Femme
  • Nora AI
  • Learn
    • Investing School
    • Q&A
    • Analysis School
  • About Us
    • Our Coverage
    • Team

You seem to be using a wider screen, would you like to enable a wider viewing experience on this page?

Mendus: Changing the course of cancer treatment

Mendus

Mendus is a clinical-stage biotechnology company developing cellular immunotherapies for cancer. As a pre-revenue company, Mendus' risk profile is high, as unfavorable research results can lead to a permanent loss of capital. These risks are offset by significant upside potential if commercialization is successful. Analyst Antti Siltanen tells more about the company in this interview.

Content: 

00:00 Intro
00:15 Mendus in a nutshell
00:41 Vididencel in a nutshell
01:35 How does Vididencel from available drugs in the market?
02:43 Vididencel phase II trial
04:08 Commercialization of Vididencel
04:45 Frozen products
05:35 Company’s potential in the long run
06:05 Funding
06:48 Role of manufacturing
07:49 Valuation methods
08:43 Valuation for Mendus at the moment

Stay up to date
Analyst Interviews

Recent videos

Talenom - Planned demerger and strategies of Talenom and Easor
18.12.2025 klo 12.00 Talenom
Investing in the life science sector
18.12.2025 klo 08.47
Life Science Companies as Investments | Life Science Night Dec. 9, 2025
16.12.2025 klo 09.30 Aiforia Technologies
Truecaller, Webcast, Press Conference, 2025
15.12.2025 klo 14.00 Truecaller
Herantis Pharma as an Investment | Life Science Night Dec 9, 2025
15.12.2025 klo 14.00 Herantis Pharma
View all videos
Find us on social media
  • Inderes Forum
  • Youtube
  • Facebook
  • Instagram
  • X (Twitter)
  • Tiktok
  • Linkedin
Get in touch
  • info@inderes.fi
  • +358 10 219 4690
  • Porkkalankatu 5
    00180 Helsinki
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Terms of service
  • Privacy policy
  • Disclaimer
Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.